The Neuroscience of Grief and How to Heal Faster According to Brain Science
Huberman explains how the brain remaps lost relationships and which science-backed tools accelerate adaptive grieving.
Cognitive performance, neuroplasticity, dementia prevention, and brain aging research
886 articles
Huberman explains how the brain remaps lost relationships and which science-backed tools accelerate adaptive grieving.
A chromatin-remodeling gene called SMARCAD1 controls tau levels — and switching it off could be a new therapeutic target for Alzheimer's.
A newly identified proteasome activator, PA200, clears toxic alpha-synuclein aggregates and maintains function even when standard protein-disposal systems fail.
Une exploration mécanistique approfondie de la manière dont la signalisation hypothalamique IKKβ/NF-κB, la communication exosomale des htNSC et la dérégulation hormonale multi-axiale pilotent le vieillissement systémique — ainsi que les stratégies thérapeutiques de pointe.
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
A small trial found tocilizumab, an anti-inflammatory drug, cut depression remission rates better than SSRIs by targeting IL-6, not brain chemistry.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A JAMA Insights review breaks down how hearing aids work, their limits, and whether OTC devices stack up against prescription options.
A landmark review reframes astrocytes as multilayered processing units that regulate synapses, circuits, and brain function at multiple spatial scales.
Plongez sous la surface pour explorer comment la signalisation NF-κB, l'activation de l'IKKβ et le déclin des cellules souches hypothalamiques accélèrent le vieillissement de l'organisme — et quelles interventions peuvent ralentir ce processus.
A completed RCT tests whether trained non-clinicians can guide self-help CBT for generalized anxiety disorder in seniors.
Researchers respond to critiques of their trial showing positive airway pressure therapy may improve cognitive outcomes in Parkinson's disease.